Cleared is not chosen. Your pivotal trial proved the device is safe and effective. It did not prove that adopting it is worth the disruption to a workflow that currently functions, and those are separate arguments requiring separate evidence.
The gap between them is where most MedTech launches lose their first two quarters, and it is almost always diagnosed as something else.
Two evidence sets, one of which is funded
Clinical evidence is produced by clinical affairs, on a regulatory timeline, for a regulatory reader. It is complete, it is expensive, and it is typically finished twelve to eighteen months before commercial launch. It answers whether the device works, and in the United States it culminates in a 510(k) clearance or PMA approval.
Commercial evidence is produced by nobody in particular, on no timeline, for the surgeon and the health system. It answers whether the device is worth adopting. In most MedTech companies it exists as a slide inside a sales deck, assembled by whoever built the deck, and then reconstructed verbally and differently by every representative in every call.
The gap is not intellectual. Everyone in the organization recognizes the distinction the moment it is described. The gap is structural. Clinical affairs are not chartered to produce commercial evidence and would be exceeding its remit if it did. Marketing is not equipped to. The commercial lead assumes it exists, because a clearance exists and a clearance feels like proof.
The organizational tell
Ask three people in your company who owns commercial evidence. If you get three different answers, or if all three name a function rather than a person, the artifact does not exist, and the launch is depending on your representatives to invent it in real time at the point of sale.
What commercial evidence has to answer
These are the questions no regulator asks, and no clinical study is designed to answer. They are also, without exception, the questions that decide the purchase.
The adoption cost, quantified
What does the first case cost in operating room time compared with the current approach. What does the tenth. What does the thirtieth. A learning curve is a fact of every device adoption, not a weakness, and publishing it honestly converts better than omitting it.
The surgeon is already assuming a curve. Your silence means they assume the worst version of it, and the worst version is usually considerably worse than your real data. This is the clearest example in MedTech marketing of an omission that costs more than the disclosure would.
The comparable institution
Which hospital of similar size, case mix, and payer profile has already absorbed that cost. Comparability is the persuasive element, not prestige. A community hospital surgeon is not reassured by a marquee academic center with different resourcing, different volumes, and a dedicated research fellow absorbing the learning curve.
The six-month volume picture
What happened at that institution after adoption. Case volume, throughput, whether the device remained in routine use or quietly returned to the shelf. This is the single most requested piece of evidence in device buying and the least likely to be published, usually for the simple reason that nobody went back and asked.
The independent contact
A named clinician at that institution who has agreed to take a call and is not on your payroll. This converts at a rate no content asset approaches. It is a relationship deliverable rather than a marketing one, which is precisely why it falls into the gap between functions and never gets built.
The named failure modes
The conditions under which adoption goes badly, stated before the surgeon discovers them independently. A company that names its failure modes is read as credible. A company presenting an unbroken record is read as concealing something, because experienced clinicians know the record is never unbroken and are actively looking for what has been left out.
Why launches slip, and what gets blamed instead
A launch that misses its adoption curve produces a predictable diagnostic sequence. The commercial team is questioned first. Then the sales structure. Then the pricing. Then, eventually and expensively, the market itself.
The actual cause is frequently that the buyer never received the evidence that would have justified the change, because it was never produced. Your representatives are reconstructing it verbally in every call, inconsistently, from memory and instinct. Your best representative is doing this well, which is why their numbers look different from everyone else’s, and nobody has written down what they say.
That is the cheapest available intervention in most MedTech commercial organizations. Not another study. One person funded for six weeks to document what the top-performing representative already communicates, and to turn it into an artifact a surgeon can be sent.
The second-order cost
There is a compounding effect worth naming. A launch that underperforms in its first two quarters gets its budget reviewed, which reduces the resources available to fix the underlying cause, which extends the underperformance. By the time anyone identifies the missing evidence set, the launch has been reclassified internally as a disappointment and the political cost of investing further has risen sharply.
The window in which this is cheap to fix is before launch. It stays open for roughly one quarter afterwards and then closes.
Where this sits in the launch sequence
Commercial evidence belongs before deployment, as a required input to the gate at which you decide the product is differentiated and ready. The common pattern is that it is treated as a post-launch marketing activity, which means it is being built while the launch is already underperforming and while the organization is under pressure to explain rather than to construct.
Built before launch it is an asset. Built after it is a remediation, and it arrives at a conversation that has already been reframed as a sales execution problem, which is a conversation it cannot win.
The test for whether it exists is simple and it is worth applying literally. Name the document. Not the deck. Not the deck appendix. Not the case study PDF that describes work without proving a method. The artifact a surgeon could be sent, unaccompanied, and would open. If you cannot name it, it does not exist.
What to do before your next launch gate
One. Interview your top representative
Ask what they say when a surgeon asks what adoption will cost them. Record the answer verbatim. That is the first draft of your commercial evidence set and it already exists inside your organization, undocumented, in one person’s head.
Two. Go back to one comparable institution
Identify one that was adopted at least six months ago and ask what happened. Most companies never do this, which is why the six-month picture is missing from every launch in the category and why the first company to publish one will have a durable advantage.
Three. Fund one named owner with a deliverable and a date
This is the step that determines whether the other two survive the quarter. It is also the step most likely to be skipped, because it requires a decision rather than an activity.
Four. Make it a gate requirement, not a marketing deliverable
Gate requirements survive reorganizations and budget reviews. Marketing deliverables do not. This distinction is the difference between a fix that holds and a fix that has to be made again in eighteen months by whoever inherits the launch.
Frequently Asked Questions
What is commercial evidence in MedTech?
Commercial evidence is the set of proofs a buyer needs to justify changing an existing workflow. It covers adoption cost in operating room time, comparable institutions that have already adopted, post-adoption volume outcomes, independent clinical references, and named failure modes. It is distinct from clinical evidence, which proves safety and efficacy for regulatory purposes.
Why do MedTech product launches slip?
A frequent and under-diagnosed cause is that the commercial evidence set was never produced, so representatives reconstruct it verbally and inconsistently in every call. The shortfall is usually attributed to sales execution, pricing, or market conditions rather than to a missing artifact.
Is a 510(k) clearance a sales asset?
No. A 510(k) clearance is a regulatory permission establishing that a device is substantially equivalent to a legally marketed predicate and may be marketed. It does not address whether adoption is worth the workflow disruption, which is the question the buyer is answering.
Who should produce commercial evidence in a medical device company?
A named owner on the commercial team, with a deliverable and a date, working from what top-performing representatives already communicate. Clinical affairs is not chartered for it and marketing is typically not equipped for it, which is why it goes unproduced by default.
Should a MedTech company publish its device learning curve?
In most cases yes. Surgeons assume a learning curve exists and estimate it pessimistically without data. Publishing an honest curve with context removes the largest single adoption objection, and operating time is operational rather than clinical data.
What makes a comparable institution persuasive in a device sale?
Similarity of size, case mix, and payer profile rather than prestige. A community hospital surgeon is not reassured by an academic center with different volumes and resourcing, because the adoption cost at that center is not the adoption cost, they will experience.
When should commercial evidence be built?
Before launch, as a required input to the differentiation gate. Built afterwards, it becomes a remediation arriving at a conversation already reframed as a sales execution problem, which is considerably harder to win.
How do you know if your company has a commercial evidence set?
Name the document. Not the sales deck, not an appendix, not a case study describing work. The artifact a surgeon could be sent unaccompanied and would open. If it cannot be named, it does not exist.
EXTERNAL CITATIONS